Welcome to our dedicated page for LB Pharmaceuticals SEC filings (Ticker: LBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LB Pharmaceuticals Inc filings document a Nasdaq-listed Delaware biopharmaceutical company developing LB-102 for neuropsychiatric diseases. Registration statements describe securities offerings and capital-structure terms for common stock, while current reports record operating and financial results, clinical-development updates, material agreements and governance events.
Proxy materials cover annual meeting matters, director elections and auditor ratification. The filing record also includes disclosures on executive and board changes, compensatory arrangements, inducement equity awards, lease agreements and shareholder voting matters tied to a late-stage drug development company.
LB Pharmaceuticals Inc director granted stock options as part of equity compensation. Director William P. Kane Jr received options for 10,000 shares of common stock, giving him the right to buy those shares at an exercise price of $27.95 per share until June 2, 2036.
According to the filing, 100% of the shares underlying the option vest on the earlier of June 3, 2027 or the date of the company’s next annual meeting of stockholders, if he continues to serve through that date. After this grant, he holds options for 10,000 shares directly.
LB Pharmaceuticals Inc. director Garland J. Scott received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $27.95 per share and expire on June 2, 2036. This is a compensation-related award, not an open-market purchase or sale.
According to the terms, 100% of the shares underlying the option vest on the earlier of June 3, 2027 or the date of the company’s next annual meeting of stockholders, subject to Scott’s continuous service through the vesting date. Following the grant, Scott holds 10,000 stock options directly.
LB Pharmaceuticals Inc. Amendment No. 1 to a Schedule 13G/A reports that TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC and Chen Yu collectively disclose beneficial ownership of 1,839,489 shares of Common Stock, representing 6.4% of the class based on 28,674,827 shares outstanding as of March 23, 2026.
The filing states these shares are held of record by TCG Crossover II; voting and dispositive power is shared through the general partner and Chen Yu as sole managing member. This Amendment supplements an Original Schedule 13G filed September 18, 2025.
LB PHARMACEUTICALS INC ownership disclosure: Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson and Michael Kramarz report beneficial ownership of 1,972,369 shares of Common Stock as of March 31, 2026, including 1,500,000 shares held and 472,369 shares issuable upon exercise of a Pre-Funded Warrant. Ownership percentages use 28,674,827 shares outstanding as of March 31, 2026 reported in the issuer's Form 10-Q filed May 12, 2026. The Pre-Funded Warrant is subject to a Beneficial Ownership Limitation of 9.99%.
LB Pharmaceuticals Inc reports that Caligan Partners LP and David Johnson hold 1,438,070 shares of Common Stock, representing 5.0% of the class. The filing states the ownership percentage is based on 28,674,827 shares outstanding as of March 23, 2026.
The cover data shows the Reporting Persons have shared voting power and shared dispositive power over the 1,438,070 shares. The statement is signed by David Johnson on May 15, 2026 and cites the company address as 575 Madison Avenue, New York, NY.
JPMorgan Chase & Co. filed an amendment to a Schedule 13G/A reporting beneficial ownership of 1,427,568 shares of LB Pharmaceuticals Inc. Common Stock, representing 4.9% of the class as reported.
The filing shows sole voting power over 1,311,423 shares and sole dispositive power over 1,427,568 shares. The reported filing cites affiliated entities including JPMorgan Chase Bank, N.A. and J.P. Morgan Investment Management Inc. The amendment is signed by a Vice President on 05/13/2026.
LB Pharmaceuticals Inc filed a prospectus supplement to its Form S-1 to update the registration materials with information from its Form 10-Q for the quarterly period ended March 31, 2026.
The supplement incorporates the company’s March quarter results: combined cash, cash equivalents and marketable securities of $365.6 million, a net loss of $(19.054) million for the three months ended March 31, 2026, and 28,676,652 shares of common stock outstanding as of May 7, 2026. The filing discloses a February 2026 private placement that raised approximately $100.0 million (net proceeds ~$93.8 million) and reiterates that current capital resources are expected to fund operations into at least the second quarter of 2029.
LB Pharmaceuticals Inc. reported a larger net loss as it ramped up late-stage development of its lead drug LB-102 while significantly strengthening its balance sheet. For the quarter ended March 31, 2026, net loss widened to $19.1 million, driven by higher research and development expenses of $14.6 million and general and administrative costs of $7.5 million.
Cash, cash equivalents and marketable securities rose to $365.6 million, helped by a $100.0 million February 2026 private placement of common stock and pre-funded warrants. Operating cash burn was $23.3 million in the quarter. The company expects its current capital to fund operations into the second quarter of 2029 as it runs a Phase 3 schizophrenia trial (NOVA-2), a Phase 2 bipolar depression trial (ILLUMINATE-1), an open-label safety study (NOVA-3), and prepares a Phase 2 adjunctive major depressive disorder trial.
LB Pharmaceuticals reported first quarter 2026 results and highlighted progress on its lead drug LB-102 across multiple neuropsychiatric indications. The company ended March 31, 2026 with cash, cash equivalents and marketable securities of $365.6 million, which it expects will fund operations into the second quarter of 2029.
Research and development expenses rose to $14,645 thousand from $3,421 thousand a year earlier, and general and administrative expenses increased to $7,459 thousand from $3,008 thousand, leading to a net loss of $19,054 thousand versus $5,306 thousand. The pivotal Phase 3 NOVA-2 trial in acute schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression have been initiated, with additional Phase 2 work in adjunctive major depressive disorder planned following a $100 million private placement.